CM Life Sciences II, Inc. (CMII)
|Net Income (ttm)||n/a|
|Trading Day||May 10|
|Day's Range||11.35 - 11.35|
|52-Week Range||11.31 - 14.27|
CM Life Sciences II Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about A...
NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (Nasdaq: CMIIU) (the “Company”) today announced that holders of the Company's units sold in its initial public offering may elect to separately trade ...
SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. ...
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU), valuing the company at $1...
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine wit...
NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial...
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $276 ...
NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it closed its initial public offering of 27,600,000 units at $10.00 per unit, including 3,600,000 units issued pu...
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsiz...
CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit.
CM Life Sciences II, Inc. has filed to go public with an IPO on the NASDAQ.
CM Life Sciences II is a newly organized blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. Our sponsor is an affiliate of Eli Casdin, founder and Chief Investment Officer of Casdin Capital, and of Keith Meister, founder and Chief Investment Officer of... [Read more...]
|IPO Date |
Feb 23, 2021
|Stock Exchange |
|Ticker Symbol |